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Introduction: Changing Regulation of Pharmaceuticals: 
Issues in Pricing, Intellectual Property, Trade and Ethics 
Michael S. Mireles* 
On April 4 and 5, 2019, the University of the Pacific, McGeorge School of 
Law hosted an international and interdisciplinary conference titled, “Changing 
Regulation of Pharmaceuticals: Issues in Pricing, Intellectual Property, Trade and 
Ethics.”  The conference explored a multitude of important issues related to the 
cost of, access to and development of life saving and enhancing pharmaceuticals.  
The conference was co-organized by Professors Mike Mireles and Christopher 
Holman.  The conference was cosponsored by Drake University Law School; 
Wake Forest University Law School; Texas A&M University Law School; 
Biotechnology Innovation Organization; Gibson Dunn; Erin Dunston (Buchanan 
Ingersoll & Rooney); Schinders Law (Guangzhou, China); VIT University Law 
School in Chennai, India; Intellectual Property Law Institute of China University 
of Political Science and Law; and the Novo Nordisk Foundation and University 
of Copenhagen’s Centre for Advanced Studies in Biomedical Innovation Law. 
The conference featured over 50 speakers from academia, industry and law 
firms, including:  Abdulaziz Alkhalifa (Prince Sattam University); April 
Alexander (Pharmaceutical Care Management Association); Mamoun 
Alhamadsheh (UOP, Thomas J. Long School of Pharmacy and Health Services); 
Margo Bagley (Emory University School of Law); Sven Bostyn (University of 
Copenhagen Law School); Melissa Brand (Biotechnology Innovation 
Organization); Dhanay Cadillo Chandler (Turku Institute of Advanced Studies); 
Daniel Cahoy (Pennsylvania State University Smeal College of Business); Niraj 
Chaudhary (UOP); Mark Christiansen (UOP, Physician Assistant Program); 
Rena Conti (Boston University Questrom School of Business); Jorge Contreras 
(University of Utah School of Law); David Collum (UOP, Thomas J. Long 
School of Pharmacy and Health Services); Erin Dunston, (Buchanan, Ingersoll & 
Rooney); Samuel Ernst (Golden Gate University School of Law); Brian Frye 
(University of Kentucky Law School); Manimuthu Gandhi (VIT Law School); 
Leanne Gassaway (America’s Health Insurance Plans); Henry Greely (Stanford 
University); Shelly Gulati (UOP, School of Engineering & Computer Science); 
Gordian Hasselblatt (CMS Hasche Sigle); Keith Hatschek (UOP, Conservatory 
of Music); Yaniv Heled (Georgia State University College of Law); Peter 
Hilsenrath (UOP, Eberhardt School of Business); Christopher Holman (UMKC 
Law School and Drake University Law School); Dmitry Karshtedt (The George 
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Washington University Law School); Clark Kelso (McGeorge School of Law); 
Stephan Kirste (University of Salzburg Law School); Peter Lee (UC Davis King 
Hall School of Law); Mark Lemley (Stanford University Law School); Henry 
Liao (Schinders Law); Michael Malloy (McGeorge School of Law); Timo 
Minssen (University of Copenhagen Law School); Mike Mireles (McGeorge 
School of Law); Sean O’Connor (University of Washington Law School); Ruth 
Okediji (Harvard Law School); Emily Parento (Georgetown University Law 
School); Dushyant Pathak (UC Davis Venture Catalyst Office); Christopher 
Paulraj (USPTO); Jenny Phillips (California Department of Managed 
Healthcare); Pedro Pita Barros (Universidade Nova De Lisboa Business); Gary 
Pulsinelli (University of Tennessee Law School); Srividhya Ragavan (Texas 
A&M University Law School); PRL Rajavenkatesan (VIT Law School); George 
Randels (UOP); Simone Rose (Wake Forest University Law School); Ana 
Rutschman (Saint Louis University School of Law); Hans Sauer (Biotechnology 
Innovation Organization); Mark Schweizer (Swiss Federal Patent Court); 
Michael Sitzman (Gibson Dunn); Wendy Soe-McKeeman (California 
Association of Health Plans); Paul Subar (UOP Arthur A. Dugoni School of 
Dentistry); Brett Taylor (UOP, Gladys L. Benerd School of Education; Jay 
Thomas (Georgetown University Law School); Daniel Wadhwani (UOP, 
Eberhardt School of Business); Patrick Warto (University of Salzburg Law 
School); Timothy Welty (Drake University, College of Pharmacy and Health 
Sciences); Zheng Xuanyu (China University of Political Science and Law); Kojo 
Yelpaala (McGeorge School of Law); Liu Ying (China University of Political 
Science and Law); Helen Yu (University of Copenhagen) and Peter Yu (Texas 
A&M University Law School).  The conference website contains abstracts and 
biographies of the speakers: https://scholarlycommons.pacific.edu/crp/. 
The conference produced seven papers which are published in this issue of 
the University of the Pacific Law Review.  The first paper is authored by Henrik 
Andersen (Copenhagen Business School) and titled, “WTO Law and Prices of 
Pharmaceutical Products: Rule of Law Gaps and the Unclear Balance between 
Trade Protection, Human Rights, and IP Protection.”  Professor Andersen 
explores rule of law gaps that may lead to higher pharmaceutical prices such as a 
lack of clarity between TRIPs and competition law, and human rights and WTO 
law.  The second paper is authored by Samuel Ernst (Golden Gate University 
Law School) and titled, “The Pharmaceutical Industry’s Corrupt Price 
Discrimination System: A Single Solution?”  Professor Ernst advocates for 
allowing the importation of lower priced pharmaceuticals from the European 
Union and Canada to decrease prices in the United States or a single payer 
system.  The third paper is authored by Christopher M. Holman (UMKC Law 
School and Drake University Law School) and titled, “Congress Should Decline 
Ill-Advised Legislative Proposals Aimed at Evergreening of Pharmaceutical 
Patent Protection.”  Professor Holman challenges proposed Congressional 
legislation supposedly addressing the practice of patent evergreening and argues 
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that those proposals are generally misguided. 
The fourth article is coauthored by Jonathan Kimball (Vice President for 
Trade and International Affairs at the Association for Accessible Medicines), 
Srividya Ragavan (Texas A&M University School of Law) and Sophia Vegas 
(Association for Accessible Medicines) and titled, “Reconsidering the Rationale 
for the Duration of Data Exclusivity.”  In that paper, the authors challenge the 
length of data exclusivity based on efficiencies gained by technological change.  
The fifth article is co-authored by Simone Rose (Wake Forest University Law 
School) and Tracea Rice (Fish and Richardson) and titled, “The Biosimilar 
Action Plan: An Effective Mechanism for Balancing Biologic Innovation and 
Competition in the United States?”  The authors critique the Food and Drug 
Administration’s Biosimilar Action Plan designed to increase the amount of 
approved biosimilars and offer some solutions to raise that number. 
The sixth article is coauthored by Christopher J. Ryan, Jr. (Roger Williams 
University Law School and American Bar Foundation) and Brian L. Frye 
(University of Kentucky School of Law) and titled, “University Patents and 
Legal Expenditures.”  The authors find that an increase in patent activity by 
universities has resulted in a rise in legal expenses at an amount which calls into 
question the overall social benefit of university patenting when other behaviors 
are considered.  The seventh paper is authored by Peter K. Yu (Texas A&M 
University School of Law) and titled, “China’s Innovative Turn and the 
Changing Pharmaceutical Landscape.”  Professor Yu argues that policymakers 
dealing with China should pay close attention to regulatory changes, evolving 
perspectives and other developments occurring in that country. 
